What is Resurrect Bio?
Resurrect Bio is an innovative agricultural biotechnology firm that specializes in the development of disease-resistant crops. Spun out of the prestigious Sainsbury Laboratory in Norwich, the company utilizes a proprietary gene-editing platform to identify and reintroduce native resistance genes from wild relatives and heritage crop varieties. This approach offers a sustainable, high-performance alternative to traditional chemical crop protection methods.
Founded by industry experts Prof. Sophien Kamoun, Prof. Tolga Bozkurt, and Dr. Cian Duggan, the company occupies a unique niche at the intersection of synthetic biology and sustainable agriculture. By focusing on the genetic architecture of plant immunity, Resurrect Bio provides the seed industry with the tools necessary to enhance yield stability and environmental resilience, effectively mitigating the risks posed by evolving pathogens in a changing climate.
How much funding has Resurrect Bio raised?
Resurrect Bio has raised a total of $20.4M across 3 funding rounds:
Unspecified
$2M
Series A
$8.1M
Series A
$10.3M
Unspecified (2023): $2M with participation from SynBioVen, SHAKE Climate Change, AgFunder, and UKI2S
Series A (2026): $8.1M led by Corteva Agriscience, Uki2s, AgFunder, Pymwymic, SynBioVen, and Calculus Capital
Series A (2026): $10.3M supported by AgFunder, Pymwymic, Corteva, SynBioVen, Future Planet Capital, Calculus Capital, and Uki2s
Key Investors in Resurrect Bio
AgFunder
A global venture capital firm focused on advancing agrifood, human, and planetary health through investments in deeptech platforms, including AI, biotech, and robotics.
Pymwymic
A pioneering impact investment firm with over 30 years of experience, dedicated to restoring broken food systems by backing visionary entrepreneurs in the agriculture sector.
Corteva Agriscience
A major global agriculture company operating in seed and crop protection, providing advanced germplasm and trait technologies to optimize farm yields and sustainability.
What's next for Resurrect Bio?
With the successful closure of this latest financing, Resurrect Bio is poised to enter a critical scaling phase. The strategic focus will likely shift toward expanding its R&D capabilities and accelerating the field-testing of its gene-edited traits. By deepening its partnerships with major agricultural players, the company aims to integrate its technology into commercial seed pipelines, thereby establishing a new standard for sustainable crop protection.
The company's roadmap includes strengthening its intellectual property portfolio and navigating the regulatory landscapes of key international markets. As it continues to attract high-caliber backing, Resurrect Bio is well-positioned to lead the next industrial revolution in agriculture, driving the transition toward net-zero farming practices while ensuring global food security through scientific innovation.
